CMRX
Price
$8.46
Change
+$0.03 (+0.36%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
784.39M
51 days until earnings call
NAMS
Price
$23.36
Change
-$0.44 (-1.85%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
2.61B
57 days until earnings call
Ad is loading...

CMRX vs NAMS

Header iconCMRX vs NAMS Comparison
Open Charts CMRX vs NAMSBanner chart's image
Chimerix
Price$8.46
Change+$0.03 (+0.36%)
Volume$80.25K
Capitalization784.39M
NewAmsterdam Pharma
Price$23.36
Change-$0.44 (-1.85%)
Volume$23.46K
Capitalization2.61B
CMRX vs NAMS Comparison Chart
Loading...
CMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMRX vs. NAMS commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMRX is a Hold and NAMS is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (CMRX: $8.43 vs. NAMS: $23.80)
Brand notoriety: CMRX and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMRX: 149% vs. NAMS: 173%
Market capitalization -- CMRX: $784.39M vs. NAMS: $2.61B
CMRX [@Biotechnology] is valued at $784.39M. NAMS’s [@Biotechnology] market capitalization is $2.61B. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMRX’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • CMRX’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, both CMRX and NAMS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMRX’s TA Score shows that 3 TA indicator(s) are bullish while NAMS’s TA Score has 4 bullish TA indicator(s).

  • CMRX’s TA Score: 3 bullish, 4 bearish.
  • NAMS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CMRX is a better buy in the short-term than NAMS.

Price Growth

CMRX (@Biotechnology) experienced а +60.57% price change this week, while NAMS (@Biotechnology) price change was +13.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

CMRX is expected to report earnings on May 01, 2025.

NAMS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.61B) has a higher market cap than CMRX($784M). CMRX YTD gains are higher at: 142.241 vs. NAMS (-7.393). CMRX has higher annual earnings (EBITDA): -92.74M vs. NAMS (-180.78M). NAMS has more cash in the bank: 423M vs. CMRX (136M). NAMS has less debt than CMRX: NAMS (506K) vs CMRX (644K). NAMS has higher revenues than CMRX: NAMS (33.6M) vs CMRX (159K).
CMRXNAMSCMRX / NAMS
Capitalization784M2.61B30%
EBITDA-92.74M-180.78M51%
Gain YTD142.241-7.393-1,924%
P/E RatioN/AN/A-
Revenue159K33.6M0%
Total Cash136M423M32%
Total Debt644K506K127%
FUNDAMENTALS RATINGS
CMRX: Fundamental Ratings
CMRX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
PROFIT vs RISK RATING
1..100
46
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CMRXNAMS
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
37%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
47%
MACD
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
51%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
54%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 18 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
61%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
63%
View a ticker or compare two or three
Ad is loading...
CMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSSIX16.110.16
+1.00%
Victory Trivalent International Sm-Cp R6
AMFFX56.890.41
+0.73%
American Funds American Mutual F1
GMSMX18.480.10
+0.52%
GuideMark® Small/Mid Cap Core Service
DTGRX58.820.23
+0.39%
BNY Mellon Technology Growth A
BOSVX16.680.04
+0.24%
Bridgeway Omni Small-Cap Value N

CMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMRX has been loosely correlated with QURE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CMRX jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMRX
1D Price
Change %
CMRX100%
N/A
QURE - CMRX
57%
Loosely correlated
-2.24%
NAMS - CMRX
49%
Loosely correlated
+1.28%
AUPH - CMRX
37%
Loosely correlated
-0.49%
CRDF - CMRX
37%
Loosely correlated
-0.64%
FGEN - CMRX
35%
Loosely correlated
-5.00%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+1.28%
QURE - NAMS
49%
Loosely correlated
-2.24%
CMRX - NAMS
49%
Loosely correlated
N/A
GYRE - NAMS
32%
Poorly correlated
-3.55%
CRDF - NAMS
30%
Poorly correlated
-0.64%
IMCR - NAMS
28%
Poorly correlated
-3.28%
More